Piramal Group's spun-off research and development arm, Piramal Life Sciences today reported a net loss of Rs 37.36 crore for the fourth quarter ended March 31, 2009.
The drug R&D firm had a net profit of Rs 52 lakh in the March quarter of FY'09, Piramal Life Sciences said in a filing to the Bombay Stock Exchange.
The company listed itself on the bourses in May last year. "Since this is the first year of results of the company published subsequent to listing of shares ans as the company has not any operations during the corresponding quarter in the previous year, the figures for previous quarter are not furnished," the filing added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app